136080-22-3Relevant academic research and scientific papers
Alpha IC adrenergic receptor antagonists
-
, (2008/06/13)
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1C adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hypertrophy. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1C receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
Reductive alkylation of pyridinium salts. Part 2. Utilisation of di-, tetra- and hexa-hydropyridine esters
McCullough, Kevin J.,MacTavish, John,Proctor, George R.,Redpath, James
, p. 2553 - 2559 (2007/10/03)
4-Benzyl-4-ethoxycarbonyl-1-substituted piperidines 1 (R1 = PhCH2, PhCO; R2 = PhCH2) cyclise with polyphosphoric acid (PPA) to give spiro[indane-2,4′-piperidin]-1-ones 3 (R = PhCH2, PhCO), while 2-benzyl-2-ethoxycarbonyl-1-methylpiperidine 4 gives the N-methylspiro[indane-2,2′-piperidin]-1-one 5. 3,4,4a,5-Tetrahydrobenz[g]isoquinolin-10(2H)-one 8 arises from PPA treatment of 1-benzoyl-4-benzyl-5-ethoxycarbonyl-1,2,3,4-tetrahydropyridine 7 (R = PhCO) while o-chloranil converts 1-benzoyl-4-benzyl-4-ethoxycarbonyl-1,4-dihydropyridine 6 (R = PhCO) into 4-benzyl-3-ethoxycarbonylpyridine 9. Phenyl(tribromomethyl)mercury reacts with 1-benzoyl-4-benzyl-4-ethoxycarbonyl-1,4-dihydropyridine 2 (R1 = PhCO, R2 = PhCH2) yielding 2-benzoyl-5-benzyl-7,7-dibromo-5-ethoxycarbonyl-2-azabicyclo[4.1.0]hept-3-ene 11, and with 1-benzoyl-4-benzyl-3-ethoxycarbonyl-1,4-dihydropyridine 6 (R = PhCO) to give 2-benzoyl-5-benzyl-7,7-dibromo-4-ethoxycarbonyl-2-azabicyclo[4.1.0]hept-3-ene 12. The structure of the latter is confirmed by X-ray crystallographic analysis. Catalytic hydrogenation of 2-benzoyl-5-benzyl-7,7-dichloro-5-ethoxycarbonyl-2-azabicyclo[4.1.0]hept-3-ene 16 yields 2-benzoyl-5-benzyl-7,7-dichloro-5-ethoxycarbonyl-2-azabicyclo[4.1.0]heptane 21 which cyclises with PPA to give the tetracyclic product 22 in good yield. When 2-benzoyl-5-benzyl-7,7-dichloro-4-ethoxycarbonyl-2-azabicyclo[4.1.0]hept-3-ene 17 is hydrogenated it yields mainly 2-benzoyl-5-benzyl-7,7-dichloro-4-ethoxycarbonyl-2-azabicyclo[4.1.0]heptane 25 but the dibromo analogue 12 under the same conditions gives two components thought to be 2-benzoyl-5-benzyl-7-endo-bromo-4-ethoxycarbonyl-2-azabicyclo[4.1.0]hept-3-ene 24 and 2-benzoyl-5-benzyl-7-exo-bromo-4-ethoxycarbonyl-2-azabicyclo[4.1.0]hept-3-ene 23. Copyright 1996 by the Royal Society of Chemistry.
NITROGEN-CONTAINING SPIROCYCLES
-
, (2008/06/13)
Spirocycles of general structural formula: STR1 are Class III antiarrhythmic agents.
